Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30,494 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a.
Havrdová E, Arnold DL, Bar-Or A, Comi G, Hartung HP, Kappos L, Lublin F, Selmaj K, Traboulsee A, Belachew S, Bennett I, Buffels R, Garren H, Han J, Julian L, Napieralski J, Hauser SL, Giovannoni G. Havrdová E, et al. Among authors: han j. Mult Scler J Exp Transl Clin. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. eCollection 2018 Jan-Mar. Mult Scler J Exp Transl Clin. 2018. PMID: 29568544 Free PMC article.
Ocrelizumab efficacy in subgroups of patients with relapsing multiple sclerosis.
Turner B, Cree BAC, Kappos L, Montalban X, Papeix C, Wolinsky JS, Buffels R, Fiore D, Garren H, Han J, Hauser SL. Turner B, et al. Among authors: han j. J Neurol. 2019 May;266(5):1182-1193. doi: 10.1007/s00415-019-09248-6. Epub 2019 Feb 28. J Neurol. 2019. PMID: 30820738 Free PMC article. Clinical Trial.
Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis.
Barkhof F, Kappos L, Wolinsky JS, Li DKB, Bar-Or A, Hartung HP, Belachew S, Han J, Julian L, Sauter A, Napieralski J, Koendgen H, Hauser SL. Barkhof F, et al. Among authors: han j. Neurology. 2019 Nov 5;93(19):e1778-e1786. doi: 10.1212/WNL.0000000000008189. Epub 2019 Sep 4. Neurology. 2019. PMID: 31484710 Free PMC article. Clinical Trial.
Treatment failure in giant cell arteritis.
Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Unizony SH, et al. Among authors: han j. Ann Rheum Dis. 2021 Nov;80(11):1467-1474. doi: 10.1136/annrheumdis-2021-220347. Epub 2021 May 28. Ann Rheum Dis. 2021. PMID: 34049857 Free PMC article. Clinical Trial.
Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial.
Stone JH, Han J, Aringer M, Blockmans D, Brouwer E, Cid MC, Dasgupta B, Rech J, Salvarani C, Spiera R, Unizony SH, Bao M; GiACTA investigators. Stone JH, et al. Among authors: han j. Lancet Rheumatol. 2021 May;3(5):e328-e336. doi: 10.1016/S2665-9913(21)00038-2. Epub 2021 Mar 19. Lancet Rheumatol. 2021. PMID: 38279390
Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, Criner GJ, Kaplan-Lewis E, Baden R, Pandit L, Cameron ML, Garcia-Diaz J, Chávez V, Mekebeb-Reuter M, Lima de Menezes F, Shah R, González-Lara MF, Assman B, Freedman J, Mohan SV. Salama C, et al. Among authors: han j. N Engl J Med. 2021 Jan 7;384(1):20-30. doi: 10.1056/NEJMoa2030340. Epub 2020 Dec 17. N Engl J Med. 2021. PMID: 33332779 Free PMC article. Clinical Trial.
30,494 results
You have reached the last available page of results. Please see the User Guide for more information.